glp 1 agonist vs sglt2 inhibitor Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study Benefits of treatment with SGLT2i
Description
caution is needed for patients with a history of medullary thyroid cancer
doi: 10.1210/endo.140.11.7143 15 MeierJJNauckMAKranzDHolstJJDeaconCFGaecklerDet al
NCBI PMC
doi: 10.1038/nature05292
You have significant metabolic dysfunction and want the broadest possible metabolic benefits
None of the studies resulted in frank pancreatitis but two reported some increase in pancreatic inflammation at high levels of exenatide
